Search Results
Your search for ,200 matches 1581 pages
Showing 151 - 200Pembrolizumab With Chemoradiotherapy for FIGO 2014 Stage III–IVA Cervical Cancer
On January 12, 2024, pembrolizumab (Keytruda) was approved for use with chemoradiotherapy for treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer.1 Supporting Efficacy Data Approval was based on findings in the double-blind...
Subtype of Fusobacterium nucleatum May Be Linked to Colorectal Cancer Progression and Poor Outcomes
Researchers have found that a specific subtype of Fusobacterium nucleatum may be capable of growing within colorectal cancer, driving cancer progression, and leading to poorer outcomes following colorectal cancer treatment, according to a recent study published by Zepeda-Rivera et al in Nature. The ...
Enfortumab Vedotin-ejfv Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
On December 15, 2023, enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) was approved for patients with locally advanced or metastatic urothelial cancer.1,2 Supporting Efficacy Data Approval was based on findings in the open-label EV-302 trial (ClinicalTrials.gov...
Pembrolizumab May Improve Breast Cancer Outcomes Regardless of Age or Menopausal Status
The addition of the immunotherapy drug pembrolizumab to chemotherapy prior to and following surgery may lead to improved outcomes in patients with breast cancer regardless of their age or menopausal status, according to new findings presented by Cardoso et al at the 2024 European Breast Cancer...
Brachytherapy Boost May Decrease the Duration of Androgen-Deprivation Therapy for High-Risk Prostate Cancer
The optimal management of high-risk prostate cancer remains a topic of ongoing investigation. The quest for therapy that maximizes cancer control while minimizing toxicity is constant. Over the past decade, there has been mounting evidence that the addition of a brachytherapy boost to external-beam ...
Adjuvant Pembrolizumab in Resected Stage IIB or IIC Melanoma
As reported in the Journal of Clinical Oncology by Jason J. Luke, MD, FACP, and colleagues, the final prespecified analysis of distant metastasis–free survival in the phase III KEYNOTE-716 trial showed continued benefit with adjuvant pembrolizumab vs placebo in patients with resected stage IIB or...
Previously Untreated Advanced Urothelial Cancer: Antibody-Drug Conjugate Plus PD-1 Inhibitor
As reported in The New England Journal of Medicine by Thomas Powles, MD, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody-drug conjugate enfortumab vedotin-ejfv and the PD-1 inhibitor pembrolizumab improved progression-free and overall survival vs...
Newly Diagnosed Multiple Myeloma
“Ask yourself at every moment, ‘Is this necessary?’” —Marcus Aurelius To complement The ASCO Post’s extensive coverage of the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, here are two important abstracts selected from the meeting proceedings focusing on induction and...
Two Adjuvant Therapy Studies Show Divergent Outcomes With PD-1 Inhibitors in Renal Cell Carcinoma
In the third prespecified interim analysis of the phase III KEYNOTE-564 trial,1 adjuvant treatment with the PD-1 inhibitor pembrolizumab significantly improved overall survival compared with placebo in patients with intermediate- or high-risk clear cell renal cell carcinoma (RCC). However, a...
Lenvatinib Plus Pembrolizumab Fails to Improve Overall Survival in Recurrent or Metastatic Head and Neck Cancer
Adding the multikinase inhibitor lenvatinib to the PD-1 inhibitor pembrolizumab as initial therapy for recurrent or metastatic head and neck squamous cell carcinoma improved response rates and progression-free survival but did not lead to an overall survival advantage over pembrolizumab...
Doxorubicin Exposure and Risk of Breast Cancer in Survivors of Hodgkin Lymphoma
In a Dutch study reported in the Journal of Clinical Oncology, Neppelenbroek et al found that doxorubicin treatment was associated with an increased risk of breast cancer among adolescent and adult Hodgkin lymphoma survivors. Study Details The study involved a cohort of 1,964 female 5-year Hodgkin...
IDEA Trial: Might Radiation One Day Be Safely Omitted for Younger, Favorable-Risk, Postmenopausal Patients With Breast Cancer?
Investigators used low recurrence scores on a genomic assay as guidance for selection of favorable-risk patients, and they found most postmenopausal patients (aged 50–69) with stage I hormone receptor–positive breast cancer who omitted adjuvant radiation therapy but continued endocrine therapy for...
Neoadjuvant Chemoimmunotherapy Improves Pathologic Complete Response Rates in Subgroup Analysis of KEYNOTE-756
Pembrolizumab added to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in patients with early-stage, high-risk, estrogen receptor (ER)-positive, HER2-negative breast cancer, according to updated results of the phase III...
IDEA Trial: Might Radiation One Day Be Safely Omitted for Younger, Favorable-Risk, Postmenopausal Patients With Breast Cancer?
Investigators used low recurrence scores on a genomic assay as guidance for selection of favorable-risk patients, and they found most postmenopausal patients (aged 50–69) with stage I hormone receptor–positive breast cancer who omitted adjuvant radiation therapy but continued endocrine therapy for...
Evaluating the Use of Perioperative Chemoimmunotherapy in Resectable Gastric and Gastroesophageal Junction Cancers
Updates of two key phase III trials presented at the 2024 ASCO Gastrointestinal Cancers Symposium showed the benefit of adding a checkpoint inhibitor to standard perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) in locally advanced, resectable gastric and...
Perioperative Tislelizumab Plus Chemotherapy in Resectable NSCLC
In patients with resectable non–small cell lung cancer (NSCLC), perioperative treatment with the checkpoint inhibitor tislelizumab plus platinum-doublet chemotherapy led to a statistically significant benefit in event-free survival and a favorable trend for overall survival, investigators for the...
First-Line Ruxolitinib Combinations Boost Benefit Over Single Agent in Myelofibrosis
In two international phase III trials in myelofibrosis, drugs given in combination with the Janus kinase (JAK) inhibitor ruxolitinib in JAK inhibitor–naive patients significantly improved outcomes vs ruxolitinib alone. Both studies were presented at the 2023 American Society of Hematology Annual...
Molecular Subtype–Based Therapy in the First-Line Treatment of Metastatic or Recurrent Triple-Negative Breast Cancer
In a Chinese single-institution phase II trial (FUTURE-SUPER) reported in The Lancet Oncology, Fan et al found that molecular subtype–based therapy produced promising results in the first-line treatment of metastatic or recurrent triple-negative breast cancer. Study Details In the open-label...
Metastatic Castration-Resistant Prostate Cancer: LuPSMA vs Cabazitaxel
As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, the Australian phase II TheraP trial has shown similar overall survival with lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) vs cabazitaxel in patients with prostate-specific membrane...
Adjuvant Treatment of Resected Melanoma: mRNA-Based Personalized Therapy Plus Immunotherapy
In the phase IIb KEYNOTE-942 trial reported in The Lancet, Jeffrey S. Weber, MD, PhD, and colleagues found that the addition of adjuvant mRNA-4157—a novel mRNA-based individualized neoantigen therapy—to pembrolizumab numerically improved recurrence-free survival in patients with completely resected ...
Sacituzumab Govitecan Plus Pembrolizumab in Metastatic Urothelial Cancer Progressing After Platinum-Based Chemotherapy
In a cohort of the phase II TROPHY-U-01 trial (cohort 3) reported in the Journal of Clinical Oncology, Petros Grivas, MD, PhD, and colleagues found that the combination of sacituzumab govitecan-hziy and pembrolizumab showed activity in patients with metastatic urothelial cancer and disease...
AMBASSADOR: Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma
Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. The Alliance for Clinical Trials in Oncology announced positive results from the phase III AMBASSADOR (A031501) trial for the adjuvant treatment of patients with localized...
Neoadjuvant Chemoimmunotherapy Improves Pathologic Complete Response Rates in Subgroup Analysis of KEYNOTE-756
Pembrolizumab added to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in patients with early-stage, high-risk, estrogen receptor (ER)-positive, HER2-negative breast cancer, according to updated results of the phase III...
Final Overall Survival Analysis of CLEAR/KEYNOTE-581: Lenvatinib/Pembrolizumab vs Sunitinib in First-Line Treatment of Advanced RCC
As reported in the Journal of Clinical Oncology by Robert J. Motzer, MD, and colleagues, the prespecified final overall analysis of the phase III CLEAR/KEYNOTE-581 trial supported a benefit of lenvatinib/pembrolizumab vs sunitinib in the first-line treatment of advanced renal cell carcinoma. The...
American Cancer Society Annual Report Shows Cancer Mortality Still Declining, but Cancer Incidence Is Projected to Top 2 Million
Although overall cancer mortality has continued to decline, resulting in over 4 million fewer deaths in the United States since 1991, increasing incidence for 6 of the top 10 cancers pushed the projected number of new diagnoses to over 2 million (2,001,140) for the first time, according to the...
FDA Approves Pembrolizumab Plus Chemoradiotherapy for FIGO 2014 Stage III–IVA Cervical Cancer
On January 12, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with chemoradiotherapy for patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer. KEYNOTE-A18 Efficacy was evaluated in KEYNOTE-A18...
Locally Advanced Cervical Cancer: Addition of Camrelizumab to Neoadjuvant Chemotherapy
In the Chinese phase II NACI trial reported in The Lancet Oncology, Li et al found that neoadjuvant chemotherapy plus camrelizumab produced antitumor activity and had a manageable adverse event profile in patients with locally advanced cervical cancer. Study Details A total of 85 patients were...
Neoadjuvant/Adjuvant Pembrolizumab in Resectable NSCLC
On October 16, 2023, pembrolizumab was approved for use with platinum-containing chemotherapy as neoadjuvant treatment and as single-agent adjuvant treatment in patients with resectable (tumors ≥ 4 cm or node-positive) non–small cell lung cancer (NSCLC).1 Supporting Efficacy Data Approval was based ...
Overall Survival With LuPSMA vs Cabazitaxel in Previously Treated Patients With Metastatic Castration-Resistant Prostate Cancer
As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, overall survival results from the Australian phase II TheraP trial showed no difference with lutetium-177–labeled PSMA-617 (LuPSMA) vs cabazitaxel in patients with metastatic castration-resistant prostate cancer and...
5-Year Outcomes of the IDEA Trial: Omission of Radiotherapy After Breast-Conserving Surgery for Low-Risk Patients
As reported in the Journal of Clinical Oncology by Reshma Jagsi, MD, DPhil, and colleagues, a 5-year analysis of the IDEA trial showed a very low rate of recurrence with the omission of radiotherapy after breast-conserving surgery in patients at low clinical and genomic risk for disease ...
Advanced NSCLC: Adding Canakinumab to First-Line Chemoimmunotherapy
As reported in the Journal of Clinical Oncology by Tan et al, the phase III CANOPY-1 trial has shown no survival benefits with the addition of canakinumab to first-line pembrolizumab plus chemotherapy in patients with advanced/metastatic non–small cell lung cancer (NSCLC) without EGFR or ALK...
FDA Approves Enfortumab Vedotin-ejfv With Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial cancer. The FDA previously granted accelerated approval to this combination for patients...
Bezuclastinib May Reduce Symptoms in Patients With Nonadvanced Systemic Mastocytosis
The targeted therapy bezuclastinib may be safe and effective at reducing markers of disease burden and improving symptoms in patients with nonadvanced systemic mastocytosis, according to recent findings published by Bose et al at the 2023 American Society of Hematology (ASH) Annual Meeting &...
Potential Underlying Genetic Mutations Identified in Patients With Myelodysplastic Syndromes
Researchers may have uncovered the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes and other myeloid neoplasms, according to new findings presented by Chaudhry et al at the American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract...
AI Model May Help Distinguish Between Two Rare Hematologic Malignancies
A novel artificial intelligence (AI) model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia, according to new findings presented by Srisuwananukorn et al at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition...
First-Line Treatment of Advanced HCC: Addition of Pembrolizumab to Lenvatinib
As reported in The Lancet Oncology by Josep M. Llovet, MD, and colleagues, the phase III LEAP-002 trial has shown that the addition of pembrolizumab to lenvatinib in the first-line treatment of unresectable hepatocellular carcinoma did not reach statistical superiority thresholds for overall or...
FDA Grants Accelerated Approval to Pirtobrutinib for CLL/SLL
On December 1, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib (Jaypirca) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a Bruton’s tyrosine...
Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC
In the phase II SPRINT trial reported in the Journal of Clinical Oncology, Ohri et al found that a chemotherapy-sparing regimen of pembrolizumab with risk-adapted radiotherapy was associated with good outcomes in patients with stage III or unresectable stage II non–small cell lung cancer (NSCLC)...
Adding Atezolizumab to Perioperative Chemotherapy in Resectable Esophagogastric Cancer
As reported in the Journal of Clinical Oncology by Lorenzen et al, the phase II portion of the German-Swiss phase II/III DANTE/IKF-s633 trial showed promising results with the addition of atezolizumab to perioperative chemotherapy in patients with resectable esophagogastric cancer. Study Details In ...
Adding Pembrolizumab to Chemotherapy for Previously Untreated Advanced Pleural Mesothelioma
As reported in The Lancet by Chu et al, a phase III trial conducted in Canada, Italy, and France showed that the addition of pembrolizumab to chemotherapy improved survival in previously untreated patients with advanced pleural mesothelioma. Study Details In the multicenter open-label trial, 440...
FDA Amends Pembrolizumab’s Gastric Cancer Indication
On November 7, the U.S. Food and Drug Administration (FDA) revised the existing indication of pembrolizumab (Keytruda) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic...
Addition of Tumor Treating Fields Therapy to Standard Systemic Therapy Improves Survival in Metastatic NSCLC after Progression on Platinum-Based Therapy
In a phase III trial (LUNAR) reported in The Lancet Oncology, Ticiana Leal, MD, Winship Cancer Institute at Emory University, and colleagues found that the addition of Tumor Treating Fields (TTFields) therapy to standard systemic therapy improved overall survival in patients with metastatic...
Metastatic Castration-Resistant Prostate Cancer: Single-Dose LuPSMA Plus Maintenance Pembrolizumab
In a single-institution phase I dose-expansion trial reported in The Lancet Oncology, Aggarwal et al found that a single dose of lutetium-177–PSMA-617 (LuPSMA) followed by pembrolizumab maintenance was associated with activity in patients with metastatic castration-resistant prostate cancer. Study...
Adding Pembrolizumab to Trastuzumab and Chemotherapy in HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma: KEYNOTE-811
In interim analyses from the phase III KEYNOTE-811 trial reported in The Lancet, Yelena Y. Janjigian, MD, and colleagues found that the addition of pembrolizumab to trastuzumab and chemotherapy in first-line treatment of patients with locally advanced or metastatic HER2-positive...
Addition of First-Line Pembrolizumab to Chemotherapy, With or Without Bevacizumab, in Advanced Cervical Cancer: Final Overall Survival Results From KEYNOTE-826
In an analysis reported in the Journal of Clinical Oncology, Bradley J. Monk, MD, FACS, FACOG, and colleagues described final overall survival results from the phase III KEYNOTE-826 trial, which evaluated the addition of first-line pembrolizumab to chemotherapy, with or without bevacizumab, in...
First-Line Selpercatinib vs Chemotherapy With or Without Pembrolizumab in RET Fusion–Positive NSCLC
An interim analysis of the phase III LIBRETTO-431 trial has shown significantly improved progression-free survival with first-line selpercatinib vs platinum-based chemotherapy with or without pembrolizumab in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC). The...
Addition of First-Line Pembrolizumab to Chemotherapy in HER2-Negative Advanced Gastric Cancer
As reported in The Lancet Oncology by Sun Young Rha, MD, and colleagues, the phase III KEYNOTE-859 trial has shown that the addition of first-line pembrolizumab to chemotherapy was associated with a statistically significant improvement in overall survival in patients with HER2-negative advanced...
FDA Approves Pembrolizumab Plus Chemotherapy for Biliary Tract Cancer
On October 31, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) to be used with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. KEYNOTE-966 Efficacy was evaluated in KEYNOTE-966...
Pembrolizumab Plus Lenvatinib as Second- and Third-Line Treatments of Pleural Mesothelioma
In a Dutch single-institution phase II trial (PEMMELA) reported in The Lancet Oncology, Douma et al found that the combination of pembrolizumab and lenvatinib showed activity as second- and third-line treatments of patients with pleural mesothelioma. Study Details A total of 38 evaluable patients...
Mind-Body Fitness Classes May Reduce Unplanned Hospitalizations, Urgent Care Visits During Cancer Care
Participation in virtual mind-body fitness classes may be effective at reducing hospitalizations, urgent care visits, and the length of hospital stays among patients with cancer by about 50%, according to new findings presented by Mao et al at the 2023 ASCO Quality Care Symposium (Abstract 473)....
